# US 2021/0003571 A1 · Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0003571 A1
- Document ID: US20210003571A1
- Status: Published application
- Kind: A1
- Application number: 17/006,374
- Filed: 2020-08-28
- Published: 2021-01-07
- Earliest claimed: 2009-11-05
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Atsushi KUMANOGOH
- Web page: https://patentgrep.com/patent/US20210003571A1

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/18: against material from animals or humans
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

## Claims

### Claim 1

A method for suppressing migration of dendritic cells to regional lymph nodes, the method comprising inhibiting binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor expressed in dendritic cells by an inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor is a Sema3A neutralizing antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Sema3A neutralizing antibody binds to a peptide comprising the amino acid sequence of from amino acid 363 to amino acid 381 of SEQ ID No: 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amino acid sequence of the peptide is NYQWVPYQGRVPYPRPGTC (SEQ ID No. 12).

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is a Neuropilin-1 neutralizing antibody.

### Claim 6 (depends on 5)

The method of claim 5, wherein the Neuropilin-1 neutralizing antibody binds to a peptide comprising the amino acid sequence of from amino acid 265 to amino acid 857 of SEQ ID No: 2.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor is a neutralizing antibody that is a polyclonal antibody.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inhibitor is a neutralizing antibody that is a monoclonal antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inhibitor is a soluble Neuropilin-1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the soluble Neuropilin-1 comprises a polypeptide selected from the group consisting of:
(1) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 589 of SEQ ID NO: 2,
(2) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 857 of SEQ ID NO: 2,
(3) a polypeptide that has an amino acid sequence comprising at least one amino acid deletion, addition or substitution in the amino acid sequence of the polypeptide of (1) or (2), while retaining a Plexin-A1-Sema3A binding activity,
(4) a polypeptide encoded by a first polynucleotide that hybridizes under high stringent conditions with a second polynucleotide that encodes the polypeptide of (1) or (2), and which has a Plexin-A1-Sema3A binding activity, and
(5) a polypeptide encoded by a third polynucleotide that hybridizes under high stringent conditions with a fourth polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5, and has a Plexin-A1-Sema3A binding activity.

### Claim 11 (depends on 1)

The therapeutic agent according to claim 1, wherein the inhibitor is a soluble Neuropilin-1 derivative.

### Claim 12 (depends on 11)

The method of claim 11, wherein the soluble Neuropilin-1 derivative comprises a fused polypeptide of Fc and a soluble Neuropilin-1, wherein the soluble Neuropilin-1 is a polypeptide selected from the group consisting of:
(1) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 589 of SEQ ID NO: 2,
(2) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 857 of SEQ ID NO: 2,
(3) a polypeptide that has an amino acid sequence comprising at least one amino acid deletion, addition or substitution in the amino acid sequence of the polypeptide of (1) or (2), while retaining a Plexin-A1-Sema3A binding activity,
(4) a polypeptide encoded by a first polynucleotide that hybridizes under high stringent conditions with a second polynucleotide that encodes the polypeptide of (1) or (2), and which has a Plexin-A1-Sema3A binding activity, and
(5) a polypeptide encoded by a third polynucleotide that hybridizes under high stringent conditions with a fourth polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5, and has a Plexin-A1-Sema3A binding activity.

### Claim 13 (depends on 12)

The therapeutic agent according to claim 12, wherein the Fc comprises a polypeptide having the amino acid sequence of SEQ ID NOS: 7, 8, 9, or 10.

### Claim 14 (depends on 11)

The method of claim 11, wherein the soluble Neuropilin-1 derivative comprises a polypeptide comprising a polyethylene glycol (PEG) chain added to a soluble Neuropilin 1, wherein the soluble Neuropilin-1 is a polypeptide selected from the group consisting of:
(1) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 589 of SEQ ID NO: 2,
(2) a polypeptide comprising the amino acid sequence of from amino acid 23 to amino acid 857 of SEQ ID NO: 2,
(3) a polypeptide that has an amino acid sequence comprising one or more amino acid deletions, additions or substitutions in the amino acid sequence of the polypeptide of (1) or (2), while retaining a Plexin-A1-Sema3A binding activity,
(4) a polypeptide encoded by a first polynucleotide that hybridizes under high stringent conditions with a second polynucleotide that encodes the polypeptide of (1) or (2), and which has a Plexin-A1-Sema3A binding activity, and
(5) a polypeptide encoded by a third polynucleotide that hybridizes under high stringent conditions with a fourth polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5, and has a Plexin-A1-Sema3A binding activity.
